Literature DB >> 16671576

Preventive and therapeutic effects of alpha-acid glycoprotein in mice infected with B. anthracis.

I G Shemyakin1, A L Pukhalsky, V N Stepanshina, G V Shmarina, V A Aleshkin, S S Afanas'ev.   

Abstract

We studied the effects of alpha1-acid glycoprotein preparations on the survival rate of BALB/c mice infected with the lethal dose of B. anthracis STI-1. Apart from native alpha1-acid glycoprotein from donor blood, we studied 3 glycoforms differing in the affinity for concanavalin A and structure of carbohydrate chains. The protective effect of alpha1-acid glycoprotein preparations did not depend on its dose and was observed 3 months after treatment (0.3 mg per mouse). The protective effect was revealed in mice receiving alpha1-acid glycoprotein preparations 2 h before infection and 24 h after inoculation of the bacterial culture. In the latter case the survival rate of animals was much higher compared to that observed in preventive administration of alpha1-acid glycoprotein. The protective effect practically did not depend on the time of treatment with glycoforms. Pretreatment with alpha1-acid glycoprotein preparations significantly decreased plasma interferon-gamma concentration. Administration of the test preparations 24 h after infection decreased the concentration of tumor necrosis factor-alpha.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16671576     DOI: 10.1007/s10517-005-0514-9

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Comparison of methods for the purification of alpha-1 acid glycoprotein from human plasma.

Authors:  Teresa R McCurdy; Varsha Bhakta; Louise J Eltringham-Smith; Sharon Gataiance; Alison E Fox-Robichaud; William P Sheffield
Journal:  J Biomed Biotechnol       Date:  2011-03-08

2.  Acute Phase Proteins and Vitamin D Seasonal Variation in End-Stage Renal Disease Patients.

Authors:  Małgorzata Maraj; Paulina Hetwer; Paulina Dumnicka; Piotr Ceranowicz; Małgorzata Mazur-Laskowska; Anna Ząbek-Adamska; Zygmunt Warzecha; Beata Kuśnierz-Cabala; Marek Kuźniewski
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.